IGF-1 and Its Role in Disease Development (G28394)

Target Name: IGHV4-39

NCBI ID: G28394

IGHV4-39

Other Name(s): IGHV439 | immunoglobulin heavy variable 4-39 | Immunoglobulin heavy variable 4-39 | VH

IGF-1 and Its Role in Disease Development

IGHV4-39 (IGHV439) is a human insulin growth factor (IGF) receptor type IIB fusion gene that is expressed in various tissues of the body. IGF-1 is a transmembrane protein that plays a crucial role in the growth and development of many tissues , including muscles, bones, and organs. IGF-1 is often referred to as the \"growth hormone,\" as it promotes cell growth and survival by stimulating the production of insulin-like growth factors (IGFs).

IGF-1 is expressed in the liver, kidneys, pancreas, and tissue (such as muscle and bone cells) and its levels are regulated by the brain. High levels of IGF-1 have been linked to various diseases, including cancer, obesity, and diabetes. In addition, IGF-1 has also been shown to be a potential drug target and biomarker for various diseases.

One of the main functions of IGF-1 is to promote cell growth and survival. It does this by stimulating the production of IGF-1 itself and by inhibiting the production ofIGF-1R, a protein that regulates IGF-1 signaling.IGF-1R is a negative regulator of IGF-1 signaling, which means that it works to keep the level of IGF-1 in the cell low.

IGF-1 has been shown to be involved in the development and progression of various diseases, including cancer, obesity, and diabetes. For example, high levels of IGF-1 have been linked to the development of various types of cancer, including breast, ovarian, and prostate cancer. IGF-1 has also been shown to be involved in the development of obesity, as it has been shown to contribute to the development of metabolic syndrome, a condition that is characterized by a combination of obesity, type 2 diabetes , and other health problems.

In addition, IGF-1 has also been shown to be involved in the development of diabetes. IGF-1 has been shown to contribute to the development of insulin resistance, which is the ability of the body's cells to resist the effects of insulin. This is a key factor in the development of type 2 diabetes, as insulin resistance allows the body's cells to become less responsive to insulin and to require higher levels of insulin to maintain normal blood sugar levels.

IGF-1 has also been shown to be involved in the regulation of bone density and fractures. It has been shown to contribute to the development of osteoporosis, a condition in which the bones become weak and fragile due to a loss of bone mass. -1 has also been shown to contribute to the development of fractures, as it has been shown to contribute to the development of bone loss and fragility.

In addition, IGF-1 has also been shown to be involved in the regulation of muscle mass and function. It has been shown to contribute to the development of muscle dystrophy, a condition in which muscle strength and function are affected, and IGF-1 has been shown to contribute to the development of muscle wasting, as a result of a loss of muscle mass.

IGF-1 has also been shown to be involved in the regulation of skin health and function. It has been shown to contribute to the development of skin diseases, including acne and psoriasis, and IGF-1 has been shown to contribute to the development of skin aging, as a result of a loss of skin cell density.

In conclusion, IGHV4-39 (IGHV439) is a protein that is involved in the development and regulation of various diseases, including cancer, obesity, diabetes, and osteoporosis. Its levels are regulated by the brain and have been shown to be involved in the development and progression of these diseases. As a result, IGHV4-39 (IGHV439) may be a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of IGHV4-39 (IGHV439) in the development and regulation of these diseases.

Protein Name: Immunoglobulin Heavy Variable 4-39

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV4-39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV4-39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets